Novo Nordisk's Wegovy Gains FDA Approval for MASH Treatment
TL;DR Summary
The FDA has approved Novo Nordisk's Wegovy for use against metabolic dysfunction-associated steatohepatitis (MASH), expanding its indications for weight loss therapy to include this liver disorder.
- Novo Nordisk wins FDA label expansion for Wegovy against liver disease MASH Seeking Alpha
- Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH Reuters
- Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis PR Newswire
- Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH Yahoo Finance
- Novo Nordisk’s obesity drug Wegovy cleared to treat MASH statnews.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
70%
87 → 26 words
Want the full story? Read the original article
Read on Seeking Alpha